Side-by-side comparison of AI visibility scores, market position, and capabilities
FICO Score powers 90% of US lending decisions; $1.72B FY2024 revenue; 10-15% annual score price increases drive operating leverage; NYSE: FICO competes with VantageScore after 2023 FHFA ruling.
Fair Isaac Corporation (FICO) is the creator of the FICO Score—the dominant consumer credit score used in approximately 90% of U.S. lending decisions—and a provider of enterprise analytics and decision management software. Founded in 1956 by engineer Bill Fair and mathematician Earl Isaac in San Jose, California, FICO is now headquartered in Bozeman, Montana and trades on NYSE (FICO). The company reported approximately $1.72 billion in revenues for fiscal year 2024 (ending September 30) under CEO Will Lansing, split between two segments: Scores (FICO Score licensing to lenders and consumer credit bureau services) and Software (Falcon Platform for fraud detection, origination decision management, and customer engagement). FICO's stock has been one of the top-performing S&P 500 components over the past decade, compounding at over 30% annually as the company's pricing power and recurring revenue model became fully appreciated by investors.
Global pharma company with $55B 2024 revenue; successfully diversifying beyond Humira with Skyrizi, Rinvoq, and $8.7B Cerevel neuroscience acquisition.
AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Spun off from Abbott Laboratories in 2013 and headquartered in North Chicago, Illinois, AbbVie rapidly became one of the world's top pharmaceutical companies on the strength of Humira — the world's best-selling drug for over a decade with peak annual sales exceeding $20 billion. AbbVie is listed on the NYSE and is a component of the S&P 500 and Dow Jones Industrial Average.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.